New pill targets Hard-to-Treat cancers driven by MYC genes
Disease control
Ongoing
This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…
Phase: PHASE1, PHASE2 • Sponsor: Monte Rosa Therapeutics, Inc • Aim: Disease control
Last updated May 15, 2026 16:38 UTC